Rankings
Pricing
Log In
Free Trial
US-listed companies
iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc.
ITOS
Market cap
$358.57M
P/E ratio
Add to your list
Add to your list
Back to summarized table
B
M
K
USD
Annual
Quarterly
Download CSV
Income statement
Balance sheet
Cash flow
Dec 31,
2020
Dec 31,
2021
Dec 31,
2022
Cash and cash equivalents
336
849
285
Short-Term Investments
-
-
328
Grants receivable
0
4
1
Research and development tax credits receivable
0
1
-
Refundable income taxes
-
8
1
Prepaid expenses and other current assets
3
14
13
Total current assets
340
875
628
Property and equipment, net
1
2
2
Long-Term Investments
-
-
118
Research And Development Tax Credit Receivable Non Current
3
2
1
Restricted cash
0
0
0
Right of use assets
-
5
5
Other assets
0
0
0
Total assets
345
885
755
Accounts payable
3
5
8
Accrued expenses and other current liabilities
7
17
20
Deferred income
4
1
1
Deferred revenue
-
280
13
Lease liabilities
-
1
1
Total current liabilities
15
304
42
Grants repayable
6
6
7
Operating Lease, Liability, Noncurrent
-
5
4
Unrecognized tax benefits
-
17
39
Other noncurrent liabilities
0
0
-
Total liabilities
21
332
92
Common Stock, Value, Issued
0
0
0
Additional paid-in capital
396
413
436
Accumulated other comprehensive (loss)
1
-1
-10
Retained earnings
-74
141
237
Total stockholders' equity
323
553
663
Total liabilities and stockholders' equity
345
885
755